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harmaceuticals are a critical component of modern
medical care and have contributed substantially to health
and quality of life. They are also expensive, accounting for
10% of US health care costs.1 By the end of this year,
Medicare beneﬁciaries are expected to spend $343 billion on
medications, and drug spending is projected to grow faster
than both the inpatient and outpatient care categories.2
Commercial and public payers use a range of mechanisms to
constrain these costs, including formularies, tiered copayments, and preauthorization. These coverage policies may
have potent impacts on medication usage, and their effects
deserve close scrutiny. In the current issue of the journal, Li
et al examine the impact of the Medicare prescription drug
program on the use of statin medications.3 The researchers
exploit the unusual design of the Medicare program to assess
how changing copayments impact both therapeutic substitution and medication discontinuation.
At its inception, the Medicare program was designed to
provide catastrophic coverage to hospitalized elderly Americans. As beneﬁciary survival increased over time, the
emphasis shifted toward management of chronic disease.4
Yet, for its ﬁrst 38 years, the program included no prescription drug beneﬁt. The Medicare Modernization Act of 2003
established the Medicare prescription drug program (known
as Medicare Part D), and coverage began in 2006.5 The drug
program added a major new entitlement for Medicare
beneﬁciaries, the cost of which was shared between beneﬁciaries and taxpayers. Even so, the plan struggled to balance
the desire for comprehensive coverage with the need for cost
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containment.6 As a compromise, comprehensive coverage
was established for indigent patients, while most beneﬁciaries
faced signiﬁcant coverage gaps. After meeting the $250
deductible, participating nonindigent patients were responsible for 25% of drug costs up to $2250, but then were
responsible for all costs until they reached the “catastrophic”
limit of $5100 (Table 1). This coverage gap between $2250
and $5100 became colloquially known as the “donut hole.”
Although many seniors beneﬁted ﬁnancially from the program,
its unusual design imposed predictable ﬁnancial shocks for
patients with multiple chronic conditions.
Using a 5% random sample of administrative claims drawn
from the Medicare Chronic Condition Warehouse in 2006, the
researchers identify patients taking branded Lipitor (atorvastatin) and Crestor (rosuvastatin) at the beginning of 2006 and
assess whether they converted to a generic alternative or
discontinued treatment. In a difference-in-differences model,
their analysis compares patients who were subject to genericonly gap coverage (study group) to propensity-matched, lowincome subsidy patients (LIS; control group). They ﬁnd that
study patients decreased branded statin use by 12%, and that
these declines were only partially offset by new generic statin
prescriptions. Relative to controls, the coverage gap was
associated with reductions in mean monthly 30-day ﬁlls of any
statin ( 0.18; CI, 0.23, 0.13) and any lipid-lowering drug
( 0.17; CI, 0.22, 0.12). The researchers conclude that
increased copayments caused some patients to switch from
branded to generic statins, whereas others discontinued them
altogether.
The study has a number of limitations. First, to be included
in the analysis, all patients spent more than $2250 on
medications in 2006, suggesting that they were sicker than

Table 1. Medicare Part D 2006 Program Design for Patients
With Incomes Greater Than 135% of the Federal Poverty Line
Drug Expenditure ($)

Patient (%)

Medicare (%)

0 to 250

100

0

251 to 2250

25

75

2251 to 5100

100

0

Over 5100

5

95
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Table 2. Medicare Part D 2017 Program Design for Patients
With Incomes Greater Than 135% of the Federal Poverty
Line14
Drug Expenditure ($)

Patient (%)

Medicare (%)

Discount (%)

0 to 400

100

0

0

401 to 3700

25

75

0

3701 to 4950

40

10

50

Over 5100

5

95

0

2006 to greater than 75% in 2014,15 and many systems
display insurance copayment tier levels at the point of
prescribing. Patients and their providers are now better able
to make informed and shared decisions in the exam room
about medications that ﬁt the patient’s medical and ﬁnancial
needs.
Drugs make an increasingly important contribution to
health care outcomes, and drug coverage policies aim to
contain costs while improving value. Ideally, coverage decisions should discourage low-value drug prescribing, encourage selection of low-cost drug options where they exist, and
encourage evidence-based prescribing. However, policies are
written to apply to all patients, and individual patient
circumstances may vary. Although conversion of branded to
generic formulations of the same drug makes sense in nearly
all circumstances, the therapeutic substitution to another
drug in the same class, as promoted by tiered copayments, is
more problematic. In particular, statin drugs vary substantially
in potency, a factor explicitly recognized in current treatment
guidelines.16 They are also metabolized differently, have
different half-lives, and vary in chemical characteristics, such
as lipophilia. These drug reimbursement policies may increase
drug-drug interactions and prompt safety concerns.17 Statin
side effects are also unfortunately common and may be
idiosyncratically speciﬁc to individual drugs.18
Although tiered pharmacy pricing coverage is commonplace, the design of the original Part D program placed the
greatest ﬁnancial burden on the sickest patients, and in the
face of sharp copayment increases, some patients choose to
forgo statins altogether. Notably, a recent economic simulation based on the MI-FREE study suggests that the opposite
approach may actually be cost saving.19 The study found that
following a myocardial infarction, provision of free evidencebased medications, including statins, would increase survival
by 0.14 quality-adjusted life years and decrease overall perpatient costs by $4011. They project that the policy would
save $2 billion annually if nationally implemented.
Given the very legitimate variations in the needs of
individual patients and the fact that many patients will
ultimately defer to their clinicians’ judgment, policies directed
to the prescriber may be more appropriate. Prescribers are
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excluded patients. Patients may respond differently to
copayments depending on their health status. Second, the
researchers appropriately used difference-in-differences
methods for the study, but they use propensity scores to
match patients who were subject to the coverage gap with LIS
patients who were not. Although they incorporate area-level
median household income as a matching criteria, by deﬁnition, LIS patients (less than $12 123 for individuals and
$16 362 for a couple) have incomes well below their area
median household income ($30 387).6 The study and control
groups are highly likely to respond differently to copayment
changes.7 As a sensitivity analysis, the researchers also
compare the study group to non-LIS patients who were not
subject to the coverage gap and ﬁnd similar results. However,
non-LIS (wealthier) patients who were not subject to the
coverage gap voluntarily enrolled in the most costly plans and
may have also responded differently to copayment changes.
Finally, patients subject to the coverage gap may have elected
to purchase branded statins internationally, but were unable
by statute to use Medicare prescription drug coverage to pay
for them. Administrative claims only document prescriptions
for which a bill was paid, and the impact of international
purchasing is unknown.
This study adds to a body of literature that ﬁnds that
patients respond to ﬁnancial incentives.1 Prescription drug
insurance coverage generally increases use of prescription
drugs and decreases cost-related nonadherence.8,9 Conversely, cost-sharing policies may decrease pharmaceutical
expenditures, but may have unintended consequences on
the use of other health services and on care outcomes.10 It is
precisely the unintended consequence of a payment policy
decreasing adherence of a proven beneﬁcial treatment that
Li et al have studied with statin prescriptions. The beneﬁts of
statins in preventing cardiovascular events are convincingly
demonstrated in multiple, large, randomized, controlled
trials11 and supported epidemiologically by observational
decreases in cardiovascular events concordant with decreases
in population cholesterol.12 Moreover, the abrupt discontinuation of statins after myocardial infarction may have detrimental effects beyond simply the absence of statins.13 Li et al
have linked a policy feature, namely, the increase in copayments for branded statins, to an overall decrease in statin
prescriptions even when a generic alternative was available.
Although Li et al effectively use a natural experiment to
show that payment policy can adversely impact evidencebased medication adherence, a number of subsequent
developments have decreased the impact of the Medicare
Part D design. First, coverage revisions have substantially
decreased ﬁnancial shocks within the donut hole (see
Table 2).14 Second, drug cost transparency is much greater
today for both patients and providers. Ambulatory electronic
health record adoption has increased from around 25% in

Impact of Cost Sharing on Therapeutic Substitution

Farmer and Borden

Disclosures
None.

References
1. Kesselheim AS, Huybrechts KF, Choudhry NK, Fulchino LA, Isaman DL, Kowal
MK, Brennan TA. Prescription drug insurance coverage and patient health
outcomes: a systematic review. Am J Public Health. 2015;105:e17–e30.
2. The Henry J. Kaiser Family Foundation. 10 essential facts about Medicare and
prescription drug spending. Available at: http://kff.org/infographic/
10-essential-facts-about-medicare-and-prescription-drug-spending/. Accessed
October 17, 2016.
3. Li P, Schwartz JS, Doshi JA. Impact of cost sharing on therapeutic substitution:
the story of statins in 2006. J Am Heart Assoc. 2016;5:e003377 doi: 10.1161/
JAHA.116.003377.
4. Anderson GF. Medicare and chronic conditions. N Engl J Med. 2005;353:305–
309.
5. Frank RG. Prescription-drug prices. N Engl J Med. 2004;351:1375–1377.
6. Oliver TR, Lee PR, Lipton HL. A political history of Medicare and prescription
drug coverage. Milbank Q. 2004;82:283–354.

DOI: 10.1161/JAHA.116.004466

7. Q1Group LLC. 2006 Medicare Part D plan overview by state archive. Available
at:
https://q1medicare.com/PartD-2006MedicarePartDSTPlanOverviews.
php. Accessed October 17, 2016.
8. Lee JL, Maciejewski M, Raju S, Shrank WH, Choudhry NK. Value-based
insurance design: quality improvement but no cost savings. Health Aff
(Millwood). 2013;32:1251–1257.
9. Khan N, Kaestner R. Effect of prescription drug coverage on the elderly’s use
of prescription drugs. Inquiry. 2009;46:33–45.
10. Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing
trends affect adherence and outcomes: a literature review. P T. 2012;37:45–
55.
11. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland
LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efﬁcacy
and safety of more intensive lowering of LDL cholesterol: a meta-analysis of
data from 170,000 participants in 26 randomised trials. Lancet.
2010;376:1670–1681.
12. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH,
Capewell S. Explaining the decrease in U.S. deaths from coronary disease,
1980-2000. N Engl J Med. 2007;356:2388–2398.
13. Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S.
Discontinuation of statin therapy following an acute myocardial infarction: a
population-based study. Eur Heart J. 2008;29:2083–2091.
14. Medicare.gov. Costs in the coverage gap. Available at: https://www.medicare.gov/part-d/costs/coverage-gap/part-d-coverage-gap.html.
Accessed
October 17, 2016.
15. The Ofﬁce of the National Coordinator for Health Information Technology.
Ofﬁce-based physician electronic health record adoption: 2004–2014. Available at: http://dashboard.healthit.gov/quickstats/pages/physician-ehradoption-trends.php. Accessed October 17, 2016.
16. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH,
Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS,
Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM,
LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B,
Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler
SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. American College of
Cardiology/American Heart Association Task Force on Practice G 2013 ACC/
AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic
cardiovascular risk in adults: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines. Circulation.
2014;129:S1–S45.
17. Devold HM, Molden E, Skurtveit S, Furu K. Co-medication of statins and
CYP3A4 inhibitors before and after introduction of new reimbursement policy.
Br J Clin Pharmacol. 2009;67:234–241.
18. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA; The National
Lipid Association’s Muscle Safety Expert P. An assessment by the Statin
Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 suppl):S58–
S71.
19. Ito K, Avorn J, Shrank WH, Toscano M, Spettel C, Brennan T, Choudhry NK.
Long-term cost-effectiveness of providing full coverage for preventive
medications after myocardial infarction. Circ Cardiovasc Qual Outcomes.
2015;8:252–259.
20. Congress.gov. H.R.2—Medicare access and CHIP reauthorization act of 2015.
Available at: https://www.congress.gov/bill/114th-congress/house-bill/2/
text. Accessed October 17, 2016.

Key Words: Editorials • health policy
research • insurance • statin therapy

and

outcomes

Journal of the American Heart Association

3

EDITORIAL

Downloaded from http://jaha.ahajournals.org/ by guest on November 8, 2017

better positioned to make informed trade-offs between costs
and outcomes than many patients are. Immediate and
effortless availability of patient-speciﬁc drug formulary
options and pricing is an important step toward achieving
greater value. Efforts to hold prescribers accountable for
generic prescribing rates, overall pharmacy costs, and patient
outcomes at the population level also have merit. Populationlevel accountability avoids the administrative inefﬁciencies of
preauthorization programs and allows prescribing ﬂexibility
for individual patients. This approach is increasingly prominent in emerging payment reforms, including the landmark
Medicare Access and Children’s Health Insurance Program
(CHIP) Reauthorization Act legislation.20
The growth of US health care spending is unsustainable,
and effective solutions are needed to improve value. Drug
spending is increasingly contributing to the cost of care, and
policies are needed to manage pharmacy utilization. Whereas
large patient pharmacy copayments almost certainly impact
drug utilization, they may be counterproductive if they
decrease use of evidence-based therapies. Policy makers
should pay careful attention to program designs to avoid
unintended consequences like those demonstrated in the
study by Li et al.
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